The role of pulmonary function in cardiometabolic endpoints

A recent study by Li G, et al. (2022) aimed to assess how pulmonary function has different risk magnitudes for cardiometabolic diseases (CD) and cardiometabolic multimorbidity (CM).

The study states that “pulmonary function could be used as a valuable predictor for the tailored prevention of individual cardiometabolic diseases and CM. Stratifying different high-risk populations through pulmonary function to implement precision medicine may have far-reaching clinical implications”.

The Vitalograph Pneumotrac was used in this study.

Read the full report. 

Vitalograph offers respiratory clinical trials solutions including ECG devices and expert cardiac analysis to ensure accurate endpoint data such as QT/QTc, as well as providing timely interpretations and alerts to support safety monitoring of subjects throughout your clinical trial.

| Vitalograph Clinical Trials |

Related Articles